Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Recon Therapeutics
AddedFeb 17, 2024
UpdatedJun 18, 2026
Recon Therapeutics

Recon Therapeutics

Angel

Recon Therapeutics: Innovating drug delivery with our patent-pending, user-friendly, and safe LyoKit System.

HQ
Boston, MA, US
Founded
2014
Overview
Compare
Fundraising
Employees

Recon Therapeutics focuses on revolutionizing drug delivery with its innovative LyoKit Disposable Reconstitution System. The LyoKit simplifies patient self-administration of biologic drugs by coupling a standard 3mL syringe with an external pressurized water chamber, enabling a one-step reconstitution process. The device is disposable and functions as its own sharps container, enhancing safety and convenience.

Recon Therapeutics has made significant strides in the healthcare industry by addressing the complexities of biologic drug administration. Their LyoKit System has been recognized for its user-friendly design and potential to improve patient compliance and safety. The company's impact is evident in its commitment to making drug delivery more accessible and efficient for patients worldwide.

Recon Therapeutics - Similar Companies

Portal Instruments logo

Portal Instruments

Love Lifesciences logo

Love Lifesciences

Replenish logo

Replenish

Enable Injections logo

Enable Injections

Credence MedSystems logo

Credence MedSystems

Enable Therapeutics logo

Enable Therapeutics

ReCode Therapeutics logo

ReCode Therapeutics

LayerBio logo

LayerBio

layerbio.com

SpringLeaf Therapeutics logo

SpringLeaf Therapeutics

Receptor Life Sciences logo

Receptor Life Sciences

receptorlife.com

Extend Biosciences logo

Extend Biosciences

extendbio.com

Micron Biomedical logo

Micron Biomedical

InSitu Biologics logo

InSitu Biologics

Syntis Bio logo

Syntis Bio

syntis.bio

Eikon Therapeutics logo

Eikon Therapeutics

eikontx.com

Recon Therapeutics - Quick Facts

Who are Recon Therapeutics' competitors?

Companies similar to Recon Therapeutics include Portal Instruments, Love Lifesciences, Replenish and Enable Injections.

When was Recon Therapeutics founded?

Recon Therapeutics was founded in 2014.

Where is Recon Therapeutics' headquarters located?

Recon Therapeutics' headquarters is located in Boston, MA, US.

When was Recon Therapeutics' last funding round?

Recon Therapeutics' most recent funding round was for $50k (USD) in October 2015.

How much has Recon Therapeutics raised to-date?

As of Oct 28, 2015, Recon Therapeutics has raised a total of $50k (USD).

How many employees does Recon Therapeutics have?

Recon Therapeutics has 3 employees as of Feb 4, 2024.

Recon Therapeutics - Classification

Industry
  • Hardware
  • Medical Devices
Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Americas
Main Product
  • Drug Delivery
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified